DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $141.67.

A number of equities analysts recently weighed in on DXCM shares. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Thursday. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Canaccord Genuity Group raised their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently modified their holdings of the company. DSM Capital Partners LLC acquired a new position in shares of DexCom in the fourth quarter valued at about $28,000. Valley National Advisers Inc. increased its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Riverview Trust Co acquired a new stake in shares of DexCom in the first quarter valued at approximately $32,000. MV Capital Management Inc. boosted its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the period. Finally, Smithfield Trust Co grew its position in DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 0.6 %

NASDAQ:DXCM opened at $128.14 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The business’s 50-day simple moving average is $133.20 and its 200-day simple moving average is $121.21. DexCom has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The stock has a market capitalization of $50.96 billion, a PE ratio of 82.67, a price-to-earnings-growth ratio of 2.19 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Sell-side analysts expect that DexCom will post 1.78 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.